Important Announcement from Zelluna ASA
Zelluna ASA has made a significant announcement regarding its corporate actions aimed at enhancing shareholder value. As part of this effort, the company, identified by its ticker symbol Oslo:ZLNA, is implementing a reverse share split that operates on a 10:1 basis. This strategic decision aims to streamline the company’s capital structure while ultimately benefiting its shareholders.
Details of the Reverse Share Split
The extraordinary general meeting, which took place recently, resolved that a reverse share split would occur. This decision is crucial for the company's future and aligns with its mission to provide value to its shareholders. The notable elements surrounding the reverse share split include:
- Date of public announcement: The action was first made known on December 19, 2024, just before the meeting.
- Approval date: The reverse split was officially approved on January 9, 2025, during the extraordinary general meeting.
- Reverse split ratio: For every ten old shares, shareholders will receive one new share, thereby decreasing the overall share count and increasing the value per share.
- Last trading day with old shares: March 31, 2025, will be the last opportunity for shareholders to trade the existing shares.
- Ex-dividend date: The new share structure will take effect on April 1, 2025. This means that any trades on this date and forward will involve the newly created shares.
- Record date: April 2, 2025, is set as the record date for the shareholders listed at that time.
ISIN Change Information
In conjunction with the reverse share split, Zelluna ASA will also transfer its shares to a new International Securities Identification Number (ISIN), which is an important identifier for trading and handling of securities. The key aspects of the ISIN change are as follows:
- Current Issuer: Zelluna ASA.
- Old ISIN: Previously, the ISIN for the company was NO 001 0851603.
- New ISIN: The newly assigned ISIN will be NO 001 3524942.
- Date of ISIN change: The transition to the new ISIN will also take effect on April 1, 2025.
Contact Information for Shareholders
The company's Chief Financial Officer, Hans Vassgård Eid, is available to address any queries or concerns regarding these changes. Shareholders and interested parties may reach him via email at hans.eid@zelluna.com or by phone at +47 482 48632.
About Zelluna ASA
Zelluna ASA is on a mission to transform cancer treatment by developing therapies that are not only effective but also safe and accessible on a global scale. Their innovative approach combines the strongest features of the immune system, especially through T cell receptor (TCR) guided natural killer (NK) cell therapies, known as TCR-NK. This novel platform has the potential to detect a wide variety of tumors, overcoming the limitations currently faced in cell therapies. Their leading program targets MAGE-A4 to treat multiple solid tumors and supports a comprehensive pipeline of future therapies.
Frequently Asked Questions
What is the purpose of the reverse share split by Zelluna ASA?
The reverse share split aims to enhance the company's share value and streamline its capital structure, benefiting shareholders.
When will the new ISIN for Zelluna ASA come into effect?
The new ISIN will take effect on April 1, 2025, coinciding with the reverse share split.
How will shareholders be affected by the reverse share split?
Shareholders will exchange ten old shares for one new share, preventing any downwards rounding of shares.
Who can I contact for more information about Zelluna ASA’s corporate actions?
Shareholders can reach out to CFO Hans Vassgård Eid via email or phone for any inquiries regarding the changes.
What innovative therapies is Zelluna ASA developing?
Zelluna ASA is pioneering TCR-NK therapies, which have the capability to overcome challenges presented by diverse tumors, aiming to provide transformative cancer treatments.
